Wockhardt in demand on getting US FDA’s approval for Fluticasone

10 Jan 2012 Evaluate

Wockhardt is currently trading at Rs 307.30, up by 11.25 points or 3.80% from its previous closing of Rs 296.05 on the BSE.

The scrip opened at Rs 298.40 and has touched a high and low of Rs 308.90 and Rs 296.00 respectively. So far 79641 shares were traded on the counter.

The BSE group 'A' stock of face value Rs 5 has touched a 52 week high of Rs 473.00 on 02-Aug-2011 and a 52 week low of Rs. 251.25 on 06-Jan-2012.

Last one week high and low of the scrip stood at Rs 308.90 and Rs 251.25 respectively. The current market cap of the company is Rs 3276.51 crore.

The promoters holding in the company stood at 73.64% while Institutions and Non-Institutions held 7.82% and 18.15% respectively. 

Wockhardt, a pharmaceutical and biotechnology major has received final approval from United States Food and Drug Administration (US FDA) for marketing 50 mcg nasal spray of Fluticasone which is used in treatment of allergic rhinitis. Fluticasone nasal spray is the generic name for the brand Flonase, marketed in the US by Glaxo Smithkline. The company is launching the product immediately.

The total market for this product in the US is about $580 million and there are only three other generic version of the product in the United States. Fluticasone nasal spray is amongst the most widely used corticosteroids in treating allergic rhinitis.

Wockhardt will be manufacturing the nasal spray at its facility in Morton Grove, Illinois, USA. The technology for this nasal spray was developed in-house.

Wockhardt Share Price

1230.95 58.60 (5.00%)
22-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.80
Dr. Reddys Lab 1213.90
Cipla 1486.30
Lupin 2069.95
Zydus Lifesciences 948.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.